- ACV reached $45M in Q3 2026 (+17% YoY) alongside $24M in Drug Discovery revenue.
- Management raised full-year 2026 guidance for both ACV and Drug Discovery revenue.
- 9-month net loss narrowed to -$91.8M vs. -$135.8M YoY, with cash and equivalents at $247.0M.
Why is $SDGR moving today? · SEC 8-K archive
$SDGR SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $SDGR: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $SDGR filing catalyst
Why did $SDGR trigger an AI stock catalyst alert?
$SDGR triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Schrödinger Reports Q3 2026: ACV Up 17% to $45M, Raises Full-Year Guidance. Key points: - ACV reached $45M in Q3 2026 (+17% YoY) alongside $24M in Drug Discovery revenue. - Management raised full-year 2026 guidance for both ACV and Drug Discovery revenue. - 9-month net loss narrowed to -$91.8M vs. -$135.8M YoY, with cash and equivalents at $247.0M.
How did $SDGR stock react after the SEC filing?
After the SEC 8-K for $SDGR, observed market reaction: T0 price $28.52. Past moves do not guarantee future results.
Where can I get real-time $SDGR SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $SDGR via Telegram and the VIP Web Terminal from €10/month.